Skip to main content
Premium Trial:

Request an Annual Quote

Vela Diagnostics Acquires Lifecode Data Interpretation Division

NEW YORK (GenomeWeb) – Vela Diagnostics announced today that it has acquired the data interpretation division of Lifecode, marking its first foray into the genomic results interpretation market.                                                                

"This acquisition puts Vela Diagnostics at the forefront in providing genomics interpretation and reporting," Vela CEO Michael Tillmann said in a statement. "The data interpretation products and services from Lifecode will be connected to Vela Diagnostics' next-generation sequencing Sentosa SQ Reporter software. This will allow for information on approved drugs, clinical trials, and publications along with somatic mutation and druggable targets for oncology based on the latest knowledge."

Singapore-based Vela said that the Lifecode division will be integrated into its Vela Genomics subsidiary, with a genomics interpretation and reporting service slated for launch in the third quarter.

Specific terms of the deal were not disclosed. This acquisition comes about three months after Lifecode was acquired by Indian diagnostics firm MedGenome.